Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €234.32 EUR
Change Today +3.12 / 1.35%
Volume 0.0
PY2 On Other Exchanges
As of 3:43 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

pharmacyclics inc (PY2) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/16/15 - €246.65
52 Week Low
05/30/14 - €61.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMACYCLICS INC (PY2)

pharmacyclics inc (PY2) Related Businessweek News

View More BusinessWeek News

pharmacyclics inc (PY2) Details

Pharmacyclics, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a first-in-class, oral, once-daily, single-agent therapy used for the treatment of patients with: chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17; mantle cell lymphoma who have received at least one prior therapy; and all lines of waldenström's macroglobulinemia (WM). Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under phase I, II, III clinical trials for the treatment of CCL, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, WM, marginal zone lymphoma, graft versus host disease, acute lymphoblastic leukemia, acute myeloid leukemia, and solid tumors and others. The company’s product candidates also comprise BTK Inhibitor Program that is in pre-clinical testing, phase I for the treatment of autoimmune; Abexinostat HDAC Inhibitor, which is in phase I and II clinical trials for treating relapsed/refractory lymphomas and solid tumors; and Factor VIIa Inhibitor, which is in phase II complete/program under review for the treatment of cancer. Pharmacyclics, Inc. has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize IMBRUVICA and certain compounds for oncology and other indications. The company was founded in 1991 and is headquartered in Sunnyvale, California.

634 Employees
Last Reported Date: 05/4/15
Founded in 1991

pharmacyclics inc (PY2) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: --
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $731.9K
Chief Operating Officer
Total Annual Compensation: $893.2K
Chief Commercial Officer
Total Annual Compensation: $379.1K
Chief of Quality & Technical Operations
Total Annual Compensation: $602.0K
Compensation as of Fiscal Year 2014.

pharmacyclics inc (PY2) Key Developments

Pharmacyclics Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015

Pharmacyclics Inc. announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $205,772,000, income from operations of $3,781,000, income before income taxes of $4,233,000, net income of $4,147,000 or $0.05 per diluted share, non-GAAP net income of $33,970,000 or $0.43 per diluted share compared to the total revenue of $119,377,000, income from operations of $18,225,000, income before income taxes of $18,263,000, net income of $18,275,000 or $0.23 per diluted share, non-GAAP net income of $31,261,000 or $0.4 per diluted share for the same quarter a year ago.

Pharmacyclics Inc.(NasdaqGS:PCYC) dropped from NASDAQ Biotechnology Index

Pharmacyclics Inc. will be removed from NASDAQ Biotechnology Index.

Pharmacyclics, Inc. Announces Initiation of PCYC-1135-CA, Multi-Center Study

Pharmacyclics Inc. announced the initiation of PCYC-1135-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational, anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca. The Phase Ib/II study will examine the safety, tolerability and effectiveness of this investigational combination in individuals with relapsed or refractory (R/R) non-small cell lung cancer (NSCLC), breast cancer, and pancreatic cancer. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech Inc. The Phase Ib portion of the study will primarily seek to determine the safety, tolerability, and appropriate dose of ibrutinib when combined with MEDI4736 to treat individuals with these cancers. The Phase II portion of the study will be conducted in three distinct cohorts to determine the safety and effectiveness of the treatment combination in individuals with R/R NSCLC, breast and pancreatic cancers. The clinical study will aim to enroll approximately 160 subjects at approximately 20 sites in the U.S.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PY2:GR €234.32 EUR +3.12

PY2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.133.00 CHF -1.40
Alexion Pharmaceuticals Inc $171.94 USD +3.37
BioMarin Pharmaceutical Inc $127.19 USD +0.31
Genmab A/S kr577.50 DKK +2.50
Vertex Pharmaceuticals Inc $125.08 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation PY2 Industry Range
Price/Earnings 100.0x
Price/Sales 24.2x
Price/Book 22.3x
Price/Cash Flow 274.3x
TEV/Sales 23.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at